The strong Phase 2 data for SPY001 in ulcerative colitis suggests a high probability of success in later-stage trials. Investors should monitor upcoming data readouts for SPY002 and SPY003 in mid-2026 and Q3 2026, respectively. The company's stock may experience positive momentum in the near term.
Price Chart
Executive Summary
Spyre Therapeutics announced positive Phase 2 topline data for SPY001 in ulcerative colitis, showing statistically significant efficacy and a favorable safety profile. The company also announced the closure of Part A enrollment and the opening of Part B for additional cohorts, indicating continued clinical progress.
Key Facts
- SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points in the Robarts Histopathology Index (RHI) score (p<0.0001)
- Key secondary endpoints included a 40% clinical remission rate and 51% endoscopic improvement rate
- SPY001 was well tolerated with a safety profile consistent with the 47 class, with no drug-related serious adverse events
- Recruitment for Part A of the SKYLINE trial is closed, and enrollment is now open for Part B
Financial Impact
The positive topline data significantly improves the drug's development prospects, potentially increasing its market value by hundreds of millions of dollars
Risk Factors
- Potential delays in regulatory approval
- Competition from other ulcerative colitis treatments
- Safety concerns in later-stage trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-024831 |
| Exhibit: exhibit991-8xkdatarelease.htm | 0001628280-26-024831 |
| Document: 0001628280-26-024831-index-headers.html | 0001628280-26-024831 |
| Document: 0001628280-26-024831-index.html | 0001628280-26-024831 |
| Document: 0001628280-26-024831.txt | 0001628280-26-024831 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | Insider Cluster | $88.98 $90.80 | ▼ −2.05% | ▼ −3.25% | $93.19 (−4.73%) |
Aug 11, 2026 7w ago | Insider Cluster | $102.74 $107.82 | ▼ −4.94% | ▼ −5.35% | $93.19 (+9.30%) |
Aug 6, 2026 8w ago | Insider Cluster | $103.42 $101.85 | ▲ +1.52% | ▲ +2.73% | $93.19 (+9.89%) |
Jul 3, 2026 13w ago | Insider Cluster | $86.63 $98.75 | ▲ +13.99% | ▲ +13.06% | $93.19 (+7.57%) |
Jun 27, 2026 13w ago | Insider Cluster | $90.16 $88.74 | ▲ +1.57% | ▲ +2.96% | $93.19 (−3.36%) |
Jun 26, 2026 14w ago | S-3ASR | $90.16 $88.74 | ▼ −1.57% | ▼ −2.96% | $93.19 (+3.36%) |
Jun 24, 2026 14w ago | Insider Cluster | $86.24 $88.89 | ▼ −3.07% | ▼ −1.37% | $93.19 (−8.06%) |
Jun 15, 2026 15w ago | 8-K | $83.58 $100.32 | ▲ +20.03% | ▲ +21.41% | $93.19 (+11.50%) |
Jun 12, 2026 16w ago | Institutional Cluster | $80.79 $88.34 | ▲ +9.35% | ▲ +8.67% | $93.19 (+15.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $80.77 $87.49 | ▲ +8.32% | ▲ +7.89% | $93.19 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access